Advertisement

European Journal of Dermatology

, Volume 24, Issue 2, pp 260–261 | Cite as

Disseminated porokeratosis transiently healed by cancer chemotherapy

  • Anne Laure Breton
  • Pauline Pralong
  • Véronique Trillet-Lenoir
  • Brigitte Balme
  • Jean-François Nicolas
  • Frédéric Berard
Correspondence

Keywords

Paclitaxel Amyloidosis Cholangiocarcinoma Keratosis Advanced Squamous Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kanitakis J, Euvrard S, Faure M, Claudy A. Porokeratosis and immunosuppression. Eur J Dermatol 1998; 8: 459–465.PubMedGoogle Scholar
  2. 2.
    Marque M, Meunier L. Porokeratosis. Ann Dermatol Venereol 2012; 139: 668–676.PubMedCrossRefGoogle Scholar
  3. 3.
    Lee H-W, Oh S-H, Choi J-C, et al. Disseminated superficial porokeratosis in a patient with cholangiocarcinoma. J Am Acad Dermatol 2006; 54(2 Suppl): S56–S58.PubMedCrossRefGoogle Scholar
  4. 4.
    Torres T, Velho GC, Selores M. Disseminated superficial porokeratosis in a patient with cholangiocarcinoma: a paraneoplastic manifestation? An Bras Dermatol 2010; 85: 229–231.PubMedCrossRefGoogle Scholar
  5. 5.
    Cannavó SP, Borgia F, Adamo B, Guarneri B. Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome? J Am Acad Dermatol 2008; 58: 657–660.PubMedCrossRefGoogle Scholar
  6. 6.
    Kono T, Kobayashi H, Ishii M, Nishiguchi S, Taniguchi S. Synchronous development of disseminated superficial porokeratosis and hepatitis C virus-related hepatocellular carcinoma. J Am Acad Dermatol 2000; 43(5 Pt 2): 966–968.PubMedCrossRefGoogle Scholar
  7. 7.
    Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96–100.PubMedCrossRefGoogle Scholar
  8. 8.
    Magee JW, McCalmont TH, LeBoit PE. Overexpression of p53 tumor suppressor protein in porokeratosis. Arch Dermatol 1994; 130: 187–190.PubMedCrossRefGoogle Scholar
  9. 9.
    Arnold SM, Regine WF, Ahmed MM, et al. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. Int J Radiat Oncol Biol Phys 2004; 58: 1411–1417.PubMedCrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2014

Authors and Affiliations

  • Anne Laure Breton
    • 1
  • Pauline Pralong
    • 1
  • Véronique Trillet-Lenoir
    • 2
  • Brigitte Balme
    • 3
  • Jean-François Nicolas
    • 4
  • Frédéric Berard
    • 4
  1. 1.Allergology and Clinical Immunology DepartmentLyon-Sud University HospitalPierre-Bénite cedexFrance
  2. 2.Medical Oncology Department, UMR 3738Lyon-Sud University HospitalPierre-Bénite cedexFrance
  3. 3.Histopathology LaboratoryLyon-Sud University HospitalPierre-Bénite cedexFrance
  4. 4.Allergology and Clinical Immunology Department, INSERM U 1111-CIRILyon-Sud University HospitalPierre-Bénite cedexFrance

Personalised recommendations